Our science is visionary.
Our commitment is relentless.
preserve vision and
prevent blindness.
About Us
Qlaris Bio is a clinical stage biotechnology company founded on a relentless commitment to develop innovative first-in-class therapies that can make a truly impactful change for patients suffering from serious and debilitating ophthalmic diseases.
Our Approach
We are exploring novel mechanisms of action to address the largest unmet needs in ophthalmology.
Our Science
Our lead asset, QLS-111, has a unique mechanism of action designed to lower intraocular pressure (IOP) by relaxing vessels of the vascular and vascular-like tissues distal to the trabecular meshwork, thereby reducing distal outflow resistance and lowering EVP.
By reducing EVP and distal outflow resistance, QLS-111 has the potential to enable the achievement of lower IOP targets than available therapies currently allow.
QLS-111 is currently in development for the treatment of Primary Open-Angle Glaucoma, Ocular Hypertension, and elevated IOP associated with rare diseases such as Sturge-Weber Syndrome.
Recent News See All News
Qlaris Bio Appoints Fred Guerard, Pharm.D., as President and Chief Executive Officer
DEDHAM, Mass., March 10, 2026 – Qlaris Bio, Inc., (“Qlaris”), a clinical-stage biotechnology company developing first-in-class therapies for glaucoma, today announced the appointment of Fred Guerard, Pharm.D., as president and chief executive officer (CEO), effective March 1, 2026. He will also join the company’s Board of Directors. Dr. Guerard brings more than two decades of […]
Qlaris Bio Appoints Robert Warner to Board of Directors
Experienced life sciences executive brings strategic and leadership expertise to support Qlaris Bio’s next phase of growth DEDHAM, Mass.–(BUSINESS WIRE)–Qlaris Bio, Inc., a clinical-stage biotechnology company focused on developing first-in-class therapies for glaucoma, today announced the appointment of Robert Warner to its board of directors. Mr. Warner’s appointment comes at a key time for Qlaris […]